Effects of Inhaled PAF in Humans on Circulating and Bronchoalveolar Lavage Fluid Neutrophils: Relationship to Bronchoconstriction and Changes in Airway Responsiveness
- 1 February 1990
- journal article
- research article
- Published by American Thoracic Society in American Review of Respiratory Disease
- Vol. 141 (2) , 386-392
- https://doi.org/10.1164/ajrccm/141.2.386
Abstract
We have compared the effect of the inhaled platelet activating factor (PAF) on circulating neutrophils with its ability to induce bronchoconstriction and bronchial hyperresponsiveness in humans. Human volunteers inhaled PAF, given as six successive inhalations 15 min apart, followed by bronchoalveolar (BAL) 4 h later. The mean density and volume of circulating neutrophils were measured by metrizamide gradients and flow cytometry, respectively. PAF caused a decreased in Vp30 of 38.2 .+-. 4.5% at 5 min after the first inhalation (p < 0.001). This was associated with a fall in the peripheral blood neutrophil count from 3.15 .+-. 0.3 to 1.1 .+-. 0.3 .times. 106 per ml (p < 0.001), followed by a rebound neutrophilia (p < 0.01). The mean density of peripheral blood neutrophils fell significantly at 15 min (p < 0.02), with a return to baseline values despite further PAF inhalations; this was associated with an increase in neutrophil volume (n = 4; p < 0.05). The numbers of neutrophils (.times. 105) in BAL fluid after PAF were significantly greater than after inhalation of lyso-PAF: 7.1 .+-. 1.4 (n = 7) versus 1.3 .+-. 0.3 (n = 5, p < 0.01); eosinophil counts did not change significantly. The PC40 (the concentration of methacholine needed to cause a fall in Vp30) decreased from 17.1 (GSEM 1.40) to 8.7 (1.44) mg/ml (n = 12, p < 0.02) 3 days after PAF. Inhaled lyso-PAF was inactive in all these respects. The degree of bronchoconstriction induced by PAF correlated positively with BAL neutrophil count (r = 0.93, p < 0.01), but the increase in PC40 correlated negatively with BAL neutrophil count (r = 0.83, p < 0.05). Our observations suggest that inhaled PAF causes activation of circulating neutrophils with subsequent infiltration into the airway and lung spaces; however, there is no evidence that these events are directly related to the development of PAF-induced hyperresponsiveness.This publication has 22 references indexed in Scilit:
- Effect of inhaled platelet-activating factor on circulating neutrophils and platelets in vivo and ex vivo in manProstaglandins, 1988
- Ketotifen inhibits the cutaneous but not the airway responses to platelet-activating factor in manJournal of Allergy and Clinical Immunology, 1988
- Accumulation of Platelets and Eosinophils in Baboon Lung after Paf-acether Challenge: Inhibition by KetotifenAmerican Review of Respiratory Disease, 1988
- Risk of anaphylaxis in patients receiving beta-blocker drugsJournal of Allergy and Clinical Immunology, 1988
- Platelet-activating factor. A potent chemotactic and chemokinetic factor for human eosinophils.Journal of Clinical Investigation, 1986
- INCREASED EXPRESSION OF THE C3B RECEPTOR BY NEUTROPHILS AND COMPLEMENT ACTIVATION DURING HEMODIALYSIS1984
- Heterogeneity of Human Peripheral Blood Eosinophils: Variability in Cell Density and Cytotoxic Ability in Relation to the Level and the Origin of HypereosinophiliaInternational Archives of Allergy and Immunology, 1983
- Partial flow-volume curves to measure bronchodilator dos-response curves in normal humansJournal of Applied Physiology, 1981
- MAJOR SPILL RESPONSE PLANNING FOR TANKER OPERATIONSInternational Oil Spill Conference Proceedings, 1979
- THE PATHOLOGY OF ASTHMA, WITH SPECIAL REFERENCE TO CHANGES IN THE BRONCHIAL MUCOSAJournal of Clinical Pathology, 1960